Feb 10, 2022

This "GABA Receptor Agonists - Pipeline Insight, 2022" report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in GABA Receptor Agonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. The assessment part of the report embraces, in depth GABA Receptor Agonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, GABA Receptor Agonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence GABA Receptor Agonists R&D. The therapies under development are focused on novel approaches to treat/improve GABA Receptor Agonists. GABA Receptor Agonists Emerging Drugs Chapters This segment of the GABA Receptor Agonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. GABA Receptor Agonists Emerging Drugs Ganaxolone: Marinus Pharmaceuticals Ganaxolone, a positive allosteric modulator of GABAA receptors, is an investigational product being developed in intravenous and oral formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone exhibits anti-seizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors. In August 2021, Marinus Pharmaceuticals announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of its lead product candidate ganaxolone, to treat seizures associated with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy. EMB-001: Embera NeuroTherapeutics EMB-001 is a patented combination product comprised of two FDA-approved medications, the cortisol synthesis inhibitor metyrapone and the benzodiazepine oxazepam. The innovation is based on insights into the physiological responses to stress in addiction. It is being developed by Embera NeuroTherapeutics and is currently in Phase II/III stage of development for the treatment of Smoking Cessation and Tobacco Use Disorder. GABA Receptor Agonists: Therapeutic Assessment This segment of the report provides insights about the different GABA Receptor Agonists drugs segregated based on following parameters that define the scope of the report. Major Players in GABA Receptor Agonists There are approx. 25+ key companies which are developing the therapies for GABA Receptor Agonists. The companies which have their GABA Receptor Agonists drug candidates in the most advanced stage, i.e. Pre-registration include, Marinus Pharmaceuticals. Key Questions How many GABA Receptor Agonists drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of GABA Receptor Agonists? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the GABA Receptor Agonists therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for GABA Receptor Agonists and their status? What are the key designations that have been granted to the emerging drugs? Key Players Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type